Somewhat Positive News Coverage Somewhat Unlikely to Affect AbbVie (ABBV) Stock Price
Media headlines about AbbVie (NYSE:ABBV) have trended somewhat positive this week, according to Accern. Accern ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. AbbVie earned a coverage optimism score of 0.16 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 47.0752216285264 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the news headlines that may have effected Accern Sentiment Analysis’s scoring:
- Is Stock’s Performance Impressive?: AbbVie Inc (NYSE: ABBV) – Alpha Beta Stock (alphabetastock.com)
- Enrapturing Stocks: AbbVie Inc. (NYSE:ABBV), Ichor Holdings, Ltd. (NASDAQ:ICHR), Bristow Group Inc. (NYSE:BRS … – The Stock Street (press release) (thestreetpoint.com)
- Amgen Gets Positive CHMP Opinion to Expand Nplate's Label (finance.yahoo.com)
- AbbVie Inc. (ABBV) EVP Sells $2,427,188.77 in Stock (americanbankingnews.com)
- Earnings Momentum Analytics Power AbbVie (ABBV) to Strong Buy (investorplace.com)
Shares of AbbVie (NYSE:ABBV) traded down $0.92 during trading on Tuesday, hitting $94.20. 795,104 shares of the company traded hands, compared to its average volume of 6,244,195. The company has a current ratio of 1.45, a quick ratio of 1.32 and a debt-to-equity ratio of 5.08. AbbVie has a 12-month low of $58.60 and a 12-month high of $98.26. The stock has a market capitalization of $152,347.31, a PE ratio of 17.97, a PEG ratio of 1.32 and a beta of 1.51.
AbbVie (NYSE:ABBV) last issued its earnings results on Friday, October 27th. The company reported $1.41 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.39 by $0.02. AbbVie had a net margin of 24.38% and a return on equity of 153.80%. The firm had revenue of $7 billion during the quarter, compared to analysts’ expectations of $7 billion. During the same quarter last year, the company posted $1.21 earnings per share. The firm’s revenue was up 8.8% compared to the same quarter last year. analysts predict that AbbVie will post 5.55 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, February 15th. Shareholders of record on Friday, January 12th will be issued a $0.71 dividend. This is a boost from AbbVie’s previous quarterly dividend of $0.64. The ex-dividend date is Thursday, January 11th. This represents a $2.84 dividend on an annualized basis and a yield of 3.01%. AbbVie’s payout ratio is presently 62.29%.
A number of equities analysts have recently issued reports on ABBV shares. Jefferies Group LLC reiterated a “buy” rating and set a $94.00 price objective (up from $92.00) on shares of AbbVie in a research note on Monday, July 17th. Deutsche Bank AG reiterated a “hold” rating and set a $66.00 price objective (up from $65.00) on shares of AbbVie in a research note on Monday, July 17th. Credit Suisse Group reiterated a “neutral” rating and set a $74.00 price objective (up from $65.00) on shares of AbbVie in a research note on Thursday, July 20th. Vetr downgraded shares of AbbVie from a “buy” rating to a “hold” rating and set a $76.28 price objective on the stock. in a research note on Thursday, July 20th. Finally, BidaskClub downgraded shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 28th. Eight equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. AbbVie has a consensus rating of “Buy” and an average target price of $93.68.
In other news, VP Robert A. Michael sold 6,699 shares of the business’s stock in a transaction dated Thursday, September 28th. The shares were sold at an average price of $88.00, for a total transaction of $589,512.00. Following the completion of the sale, the vice president now owns 10,007 shares of the company’s stock, valued at $880,616. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Azita Saleki-Gerhardt sold 8,300 shares of the business’s stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $85.02, for a total transaction of $705,666.00. Following the transaction, the senior vice president now owns 93,099 shares in the company, valued at $7,915,276.98. The disclosure for this sale can be found here. Insiders sold 58,932 shares of company stock valued at $5,379,432 in the last ninety days. 0.23% of the stock is owned by corporate insiders.
AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.
Receive News & Stock Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related stocks with our FREE daily email newsletter.